BioLife Solutions, Inc. (BULLETIN BOARD: BLFS) , a leading developer, manufacturer, and marketer of biopreservation tools for cells, tissues, and organs, today announced that Sigma-Aldrich will distribute the Company's proprietary HypoThermosol and CryoStor biopreservation media products under the terms of a non-exclusive distribution agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090814/BIOLIFELOGO)

Mike Rice, BioLife's chairman and CEO, noted, "We're pleased to have Sigma-Aldrich as a distribution partner for our biopreservation media products in the academic and clinical research markets. Clinical research customers voiced a need for better cell preservation media that did not include serum or protein components, and the value proposition of our HypoThermosol and CryoStor products aligned perfectly with this requirement. Our products are not only serum-free and protein-free, but are also manufactured under GMP in our Bothell production facility using only USP or highest available grade components. We are pleased to offer the research community fully defined, pre-formulated biopreservation media that improves post-preservation cell viability, recovery, and function."

About Sigma-Aldrich

Sigma-Aldrich is a leading Life Science and High Technology company. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com/.

About BioLife Solutions

BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol and CryoStor™ platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death. Comprehensive small animal intravenous safety studies have been completed on HypoThermosol and CryoStor, and both products are supported by US FDA Master Files. BioLife's enabling technology provides research and clinical organizations significantly enhanced post-preservation cell and tissue viability and function. For more information please visit www.biolifesolutions.com.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Sigma-Aldrich is a registered trademark of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.

  Media Relations:                        Investor Relations:
  Len Hall                                Matt Clawson
  Allen & Caron Inc                       Allen & Caron Inc
  (949) 474-4300                          (949) 474-4300
  len@allencaron.com                      matt@allencaron.com

First Call Analyst:
FCMN Contact:

SOURCE: BioLife Solutions, Inc.